Lenvatinib for Recurrent Liver Cancer After Transplant
This study is about testing a drug called lenvatinib for liver cancer, specifically hepatocellular carcinoma (HCC), that comes back after a liver transplant. HCC is a serious type of liver cancer. The study aims to see if lenvatinib can help stop the cancer from growing by blocking certain enzymes (proteins that speed up chemical reactions). This is important because there are no standard treatments for people with this type of cancer after a transplant.
In the study, people will take lenvatinib by mouth once a day. The treatment is repeated every 28 days, as long as it is working and not causing bad side effects. After finishing the treatment, participants will have check-ups for up to 2 years to see how they are doing.
- This study involves taking a pill daily and regular check-ups.
- Participants must be adults who have had liver transplants.
- People with certain health conditions or previous lenvatinib use cannot participate.
How understandable was the trial content above?
Hard to understand
Easy to understand